Track topics on Twitter Track topics that are important to you
TORONTO, ONTARIO -- (Marketwired) -- 06/04/15 -- Cynapsus Therapeutics Inc. (TSX: CTH) (OTCQX: CYNAD), a specialty central nervous system pharmaceutical company focused on the treatment of OFF episodes in Parkinson's disease, is pleased to announce the grant of U.S. Patent No. 9,044,475, an additional patent in its sublingual apomorphine portfolio. This patent is solely owned by Cynapsus and granted with claims that provide Cynapsus with protection of pharmaceutical dosage forms that combine apomorphine hydrochloride particles with an organic pH neutralizing agent and a permeation enhancer in a sublingual film. This patent is scheduled to expire in June of 2030 and covers Cynapsus' Parkinson's product candidate, APL-130277, and related formulations. APL-130277 is designed to be safe and easily self-administered by patients with Parkinson's disease.
The issued patent is the third to issue as a U.S. patent from the company's patent application filings directed to sublingual apomorphine therapies. Cynapsus' intellectual property position includes other patent applications that seek to further protect additional features of sublingual apomorphine films.
"As one of the original inventors and the CEO of Cynapsus, I am pleased that we have obtained this significant patent issuance. This U.S. patent is part of our broad based patent strategy. It is significant to Cynapsus in that it provides protection for our technology that allows for a clinically meaningful and convenient delivery method of apomorphine, the only drug to be known to rapidly turn patients ON while they are experiencing all types of OFF episodes associated with Parkinson's disease," said Mr. Anthony Giovinazzo, President and CEO.
Cynapsus is a specialty central nervous system pharmaceutical company developing and preparing to commercialize a Phase 3, fast-acting, easy-to-use, sublingual thin film for the on-demand turning ON of debilitating OFF episodes associated with Parkinson's disease.
This announcement contains "forward-looking statements" within the meaning of applicable securities laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Cynapsus to be materially different from those expressed or implied by such forward-looking statements, including but not limited to those risks and uncertainties relating to Cynapsus' business disclosed under the heading "Risk Factors" in its Annual Information Form and its other filings with the various Canadian securities regulators which are available online at www.sedar.com. Although Cynapsus has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Cynapsus does not undertake to update any forward-looking statements, except in accordance with applicable securities laws.
Neither the TSX nor the OTCQX International has approved or disapproved of the contents of this press release.Contacts: Cynapsus Therapeutics Anthony Giovinazzo President and CEO (416) 703-2449 x225 Cynapsus Therapeutics Andrew Williams COO & CFO (416) 703-2449 x253 NEXT ARTICLE
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...